Denmark has temporarily suspended the use of the Oxford-AstraZeneca vaccine as a precaution “after reports of severe cases of blood clots in people who have been vaccinated with the COVID-19 vaccine from AstraZeneca”.
According to the Danish Health Authority, it is too early to decide whether there is a connection between the vaccine and the blood clots.
The health authority has issued the following statement:
Against this background, the European Medicines Agency has launched an investigation into the AstraZeneca vaccine. One report relates to a death in Denmark. At present, it cannot be concluded whether there is a link between the vaccine and the blood clots.
The development came after Austria also suspended the use of a specific batch of the vaccine because a woman had died ten days after taking a dose of the vaccine.
Estonia, Latvia, Lithuania, and Luxemburg have also halted the use of the batch as a precautionary measure.
According to a spokesperson for AstraZeneca, the company is investigating any potentially harmful effects related to the vaccine.
“Patient safety is the highest priority for AstraZeneca. Regulators have clear and stringent efficacy and safety standards for the approval of any new medicine, and that includes the COVID-19 vaccine AstraZeneca. The safety of the vaccine has been extensively studied in Phase III clinical trials and peer-reviewed data confirms the vaccine is generally well-tolerated,” AstraZeneca said in a statement.
The Director of the National Board of Health in Denmark, Søren Brostrøm, stated that the vaccine has been suspended for 14 days until the matter has been investigated.